If the website where the corresponding drugs are presented, the Zytiga Cost in India is indicated too much, most likely, it is not worth making a purchase there. It is possible that the seller will require a small advance payment for delivery for security reasons and to ensure that the client comes to the post office for the order. This is how naive buyers are often deceived.
Quality pharmaceutical products should be ordered from trusted resources. It is sold there in the price range declared by the official manufacturer. The required certificates of conformity, certified by documents, are also attached. It is advisable to clarify the amount to be paid at the time of registration of an application for the purchase of medication. Due to the fluctuating exchange rate of currencies, the Zytiga (Abiraterone) Cost in India indicated on the site sometimes differ from the real ones.
How much Does Zytiga (Abiraterone Acetate) 250 mg Tablet Cost in India
The price of Zytiga in India (Abiraterone Acetate) is the newest drug that has found its use in the treatment of prostate cancer, even in advanced stages. According to official figures, the treatment of cancer patients with such an innovative drug has reduced mortality by 35%, increasing the survival rate for metastatic cancer. It is also important to note that Zytiga Cost in India is able to minimize pain syndrome.
As a rule, Zytiga is used more often in European countries. However, the cost of this drug is simply not affordable for most of the post-Soviet space. Therefore, leading Russian oncologists often recommend that their patients buy Abiraterone 250 mg. The action of the drug is that it suppresses the activity of an enzyme necessary for tumor growth. As a result, the production of hormones decreases, both in the adrenal glands and testes, and in the tumor.
According to oncologists, this drug is a truly revolutionary breakthrough in the treatment of cancer. It has proven to be effective even in the treatment of patients with hormone-refractory and hormone-resistant forms of the disease. It is used for metastatic prostate cancer and as a palliative agent that has a positive effect on the patient’s condition. This drug can prolong life as well as improve its quality in those who suffer from resistant forms of prostate cancer.
Benefits of generic Zytiga (Abiraterone Acetate) 250 mg Tablet
Currently, the sale of the drug Zytiga Cost in India is carried out literally everywhere. This drug inhibits the production of an enzyme that promotes the development of tumors in the prostate. The Indian generic is not inferior to the American counterpart in its properties. But its price is an order of magnitude lower. Such a drug will reduce the size of the tumor, increase the survival time and be able to withstand even aggressive forms of cancer. It is considered to be more effective than standard chemotherapy courses.
Clinical studies have repeatedly confirmed that patients who took an Indian generic with a complementary drug did indeed live longer. But, despite the high level of safety, the drug is used only as directed by an experienced oncologist. During the course, the patient needs to monitor the pressure indicators, as well as liver function.
One of the advantages of Zytiga Cost in India is that it is permissible to use it not only after a chemotherapy course, but also together with it. This drug is suitable for adult patients who do not suffer from liver dysfunction. Abiraterone is excreted naturally within 5-12 hours. In each case, the specifics of its use are agreed upon with the doctor based on the results of the examination. Self-medication is unacceptable.
After oral administration on an empty stomach, the time to reach the C max of the active substance in the blood plasma is approximately 2 hours. Taking with food, compared with fasting, leads to a 10-fold increase in AUC and a 17-fold increase in C max, depending on the fat content of the food taken. Plasma protein binding of labeled 14 C-Abiraterone is 99.8%. The apparent V d is approximately 5.630 l, which indicates that Zytiga (Abiraterone Acetate) 250 mg price actively distributed to peripheral tissues.
Abiraterone undergoes metabolism, including sulfation, hydroxylation and oxidation, mainly in the liver. Most of the circulating 14 C-Abiraterone acetate (approximately 92%) was in the form of the Abiraterone metabolite. Of the 15 detectable metabolites, each of the two major metabolites, Abiraterone sulfate and Abiraterone sulfate dioxide, accounted for 43% of the total radioactivity.
The average T 1/2 of Zytiga (Abiraterone Acetate) 250 mg in plasma is about 15 hours. With oral administration of labeled 14 C-Abiraterone acetate at a dose of 1 g, approximately 88% of the radioactive dose was excreted through the intestine and approximately 5% was excreted by the kidneys. In feces, mainly unchanged Abiraterone acetate and Abiraterone were determined (approximately 55% and 22% of the administered dose, respectively).
As part of combination therapy with low-dose prednisolone, the recommended daily dose of Abiraterone is 1 g 1 time/day 1 hour before meals or 2 hours after meals.
If during treatment, patients develop signs of hepatotoxicity (an increase in ALT activity 5 times higher than ULN or bilirubin concentration 3 times higher than ULN), therapy should be discontinued immediately until liver function indicators are completely normalized. Re-therapy in patients with normalized liver function parameters can be started with a reduced dose of 500 mg 1 time/day. If symptoms of hepatotoxicity occur at a dose of 500 mg, Abiraterone therapy should be discontinued. With the development of a severe form of hepatotoxicity (ALT activity exceeds VGN by 20 times), Abiraterone should be canceled in any period of therapy, repeated use in such cases is impossible.
From the liver: hepatotoxicity, accompanied by an increase in the activity of ALT, ACT and total bilirubin (the mechanism for the development of hepatotoxicity is currently unknown).
- From the urinary system: very often – urinary tract infections; often – hematuria.
- From the side of the cardiovascular system: very often – arterial hypertension; often – heart failure, incl. acute heart failure, left ventricular failure, decreased left ventricular ejection fraction, angina pectoris, arrhythmia, atrial fibrillation, tachycardia.
- From the digestive system: often – dyspepsia.
- From the musculoskeletal system: often – fractures (with the exception of pathological fractures).
- From the endocrine system: infrequently – adrenal insufficiency.
- From the respiratory system: rarely – allergic alveolitis.
- On the part of laboratory parameters: very often – hypokalemia; often – hypertriglyceridemia, increased ALT activity.
- General disorders: very often – peripheral edema.
Use with caution in patients with severe renal impairment, since there are no clinical data on the use in this category of patients.
Caution is necessary when used in patients whose condition may worsen with an increase in blood pressure or the development of hypokalemia, for example, with heart failure, recent myocardial infarction or ventricular arrhythmia; with left ventricular ejection fraction less than 50%, heart failure III-IV functional class according to NYHA classification. The safety of the drug in patients with left ventricular ejection fraction <50% or with NYHA functional class III-IV heart failure has not been established. Before starting the use of Abiraterone, hypokalemia and arterial hypertension should be eliminated.
In patients receiving Abiraterone, an increase in blood pressure, hypokalemia and fluid retention may be observed due to an increase in the concentration of mineralocorticoids in the blood due to inhibition of CYP17. Administration of GCS simultaneously with Abiraterone weakens the stimulating effect of ACTH, which leads to a decrease in the frequency and severity of these adverse reactions.
Blood pressure, plasma potassium concentration and the degree of fluid retention should be monitored at least once a month.
Serum transaminase activity and blood bilirubin levels should be measured before starting treatment, every 2 weeks for the first 3 months of treatment, and then monthly. With the development of clinical symptoms and signs that suggest impaired liver function, the activity of serum transaminases, in particular ALT, should be immediately determined. With an increase in ALT activity 5 times higher than ULN or bilirubin concentration 3 times higher than ULN, the use of Abiraterone should be stopped immediately; careful monitoring of liver function is necessary.
When withdrawing prednisolone, caution and control of symptoms of adrenal cortex insufficiency is necessary.
In a study evaluating the effect of Abiraterone acetate, taken in conjunction with prednisone, on dextromethorphan (a CYP2D6 substrate), when taken in a single dose, the AUC of dextromethorphan increased by approximately 200%. The AUC 24 of dectrophan, the active metabolite of dextromethorphan, increased by approximately 33%.
It is recommended to use Abiraterone with caution in patients receiving drugs that are metabolized with the participation of CYP2D6, especially for drugs with a narrow therapeutic index. In such cases, you should consider the possibility of reducing the dose, drugs, incl. dextromethorphan, metoprolol, propranolol, desipramine, venlafaxine, haloperidol, risperidone, propafenone, flecainide, codeine, oxycodone, and tramadol.
Based on in vitro data, Abiraterone is a substrate of the CYP3A4 isoenzyme. Caution is needed when taken concomitantly with strong inhibitors of the CYP3A4 isoenzyme (ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, indinavir, nelfinavir, voriconazole), rifalinabitin, rifalinabitin, rifinabitin (phenytobitin)